Delivery Order SPE2DB20D1004-SPE2DB24FF5P4
- Not listed
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccine to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for a ceiling value of $2,911.25. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is February 1, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML vaccines to the Defense Logistics Agency (DLA). The $7,255.27 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract has an ultimate completion date of November 27, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary...
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The $3,421.00 firm-fixed price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML pharmaceuticals to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,709.07, was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a subsidiary of the large pharmaceutical distribution company Amerisourcebergen Corporation. The contract is a Delivery Order under Amerisourcebergen's Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00...
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, to the Defense Logistics Agency (DLA). The $11,196.00 firm-fixed-price contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., on October 22, 2021, with a completion date of October 25, 2021. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award is for the delivery of 4,565,058,954 units of the TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccine to the Defense Logistics Agency (DLA). The $27,432.44 Firm Fixed Price Delivery Order was awarded to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical supplier to the U.S. government. The contract has an ultimate completion date of July 3, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) as a delivery order. The contract is for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a ceiling value of $9,073.58. It is a firm fixed-price delivery order contract with a completion date of June 12, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite...
- This federal contract award, valued at $2,965.89, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccine, with a completion date of February 15, 2024. AmerisourceBergen, a subsidiary of the parent company Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through...
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML vaccines to the Defense Logistics Agency (DLA), a component of the Department of Defense (DoD). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on April 28, 2022, with a ceiling value of $62,931.20 and an ultimate completion date of April 29, 2022. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant $999,999,999 Indefinite...
- This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $3,449.50 and a completion date of May 21, 2025. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm fixed-price delivery order and is not set aside for any specific business category. Amerisourcebergen Drug Corp...
- SPE2DB20D1004Indefinite Delivery Contract
- SPE2DB20D1004-SPE2DB24FF5P4Delivery Order
This federal contract award is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccines to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and subsidiary of Cencora, Inc. The contract has a ceiling value of $3,421.00 and a completion date of March 8, 2024. It is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating it was awarded through open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 3/7/24 |